|
The mission of our company is to provide a novel medical treatment for patients who suffer from cancer and incurable diseases by research and development of HGF (hepatocyte growth factor) and its intramolecular fragment NK4. Our goal is to provide original medicines for global healthcare based on the innovative drug research conducted in Japan. |
| Project |
Drug substance |
Target disease |
Development stage |
Alliance |
| NK4 |
Protein |
Solid tumors |
Pre-clinical |
To be determined |
| Gene |
Solid tumors |
Pre-clinical |
To be determined |
| HGF |
Protein i |
Acute renal failure |
Phase 1 / US ii,iii |
To be determined |
| Skin ulcers |
Phase 2 / EU iii |
Tripep AB(Sweden) |
i. Other indications for HGF to be determined.
ii. To be conducted at The Rogosin Institute, NY.
iii. Expected to begin following authority's review.
 |
The Strengths of NK4 |
|
NK4 is a highly unique, bi-functional molecule. Specifically, it inhibits the invasion and metastasis of tumor cells as an HGF-antagonist, and at the same time possesses potent antiangiogenic activity. Worthy of special mention is the fact that NK4 suppresses the action of several angiogenic factors (VEGF, bFGF, HGF). At present, the development of antiangiogenic agents is being conducted at a large number of pharmaceutical companies worldwide, but a molecule other than NK4 having such unique functions as those noted above is not yet known.
|
|
|
|
The Strengths of HGF |
|
HGF, hepatocyte growth factor, was isolated as a mitogenic protein for hepatocytes and genetically cloned for the first time by Professor Toshikazu Nakamura of Osaka University.
From subsequent research, it was found that HGF has an extremely potent regenerative healing ability in regard to not only liver cells, but a wide variety of cells and organs. In particular, the antifibrotic action of HGF is an action not seen with other growth factors and so it has the potential to become a revolutionary therapeutic agent for intractable fibrotic diseases with no method of treatment.
|
|
